Moderna Inc (MRNA)vsNuvation Bio Inc (NUVB)
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
NUVB
Nuvation Bio Inc
$6.07
-3.34%
HEALTHCARE · Cap: $2.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 1211% more annual revenue ($2.23B vs $169.90M). NUVB leads profitability with a -88.2% profit margin vs -141.4%. NUVB earns a higher WallStSmart Score of 28/100 (F).
MRNA
Avoid21
out of 100
Grade: F
NUVB
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Intrinsic value data unavailable for NUVB.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Conservative balance sheet, low leverage
Revenue surging 556.0% year-over-year
Areas to Watch
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Trading at 8.3x book value
0.0% earnings growth
ROE of -45.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bull Case : NUVB
The strongest argument for NUVB centers on Revenue Growth. Revenue growth of 556.0% demonstrates continued momentum.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Bear Case : NUVB
The primary concerns for NUVB are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
MRNA profiles as a turnaround stock while NUVB is a hypergrowth play — different risk/reward profiles.
NUVB carries more volatility with a beta of 1.53 — expect wider price swings.
NUVB is growing revenue faster at 556.0% — sustainability is the question.
NUVB generates stronger free cash flow (-5M), providing more financial flexibility.
Bottom Line
NUVB scores higher overall (28/100 vs 21/100) and 556.0% revenue growth. MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Nuvation Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?